Translate Bio Inc

NASDAQ:TBIO  
19.41
+0.67 (+3.58%)
Products, Regulatory, Earnings Announcements

Translate Bio Announces Results From Second Interim Data Analysis From Ongoing Phase 1/2 Clinical Trial Of MRT5005 In Patients With Cystic Fibrosis

Published: 03/17/2021 20:17 GMT
Translate Bio Inc (TBIO) - Translate Bio Announces Results From Second Interim Data Analysis From Ongoing Phase 1/2 Clinical Trial of Mrt5005 in Patients With Cystic Fibrosis (cf).
Translate Bio Inc - First Inhaled Mrna Therapeutic Delivered in Multiple Doses to Lungs of Cf Patients is Generally Safe and Well Tolerated.
Translate Bio Inc - No Observed Pattern of Increases in Ppfev.
Translate Bio Inc - Phase 1/2 Clinical Trial for Mrt5005 Ongoing and Next-generation Cf Candidate Anticipated to Enter Ind-enabling Studies in 2h 2021.
Revenue is expected to be $42.72 Million
Adjusted EPS is expected to be -$0.03

Next Quarter Revenue Guidance is expected to be $29.92 Million
Next Quarter EPS Guidance is expected to be -$0.30

More details on our Analysts Page.